EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Multisite Trial Assessing Efficacy and Safety

Intranasales Oxytocin bei Alkoholgebrauchsstörung: randomisierte, doppelblinde, placebokontrollierte Multizenterstudie zu Wirksamkeit und Sicherheit

Nassima Ait-Daoud Tiouririne iD, Jospeh A Legan, Eric Devine, Kristen Lee, Elise M Weerts, Jennifer D Ellis, Lara Ray iD, Steve Shoptaw, Daniel Falk, Megan Ryan, Raye Litten, Chamindi Seneviratne und 2 weitere

Alcohol, Clinical and Experimental Research · 2026-07 · 50 (7)

DOI: 10.1111/acer.70326 ↗

Auf einen Blick

Bei 100 Personen mit Alkoholgebrauchsstörung führte intranasales Oxytocin über 12 Wochen nicht zu einer signifikanten Reduktion des Trinkens gegenüber Placebo. Es war gut verträglich.

Fragestellung

Ist intranasales Oxytocin bei Alkoholgebrauchsstörung wirksam und sicher?

Methode

Randomisierte, doppelblinde, placebokontrollierte Multizenterstudie über 12 Wochen; Oxytocin bis 70 IU/Tag vs. Placebo bei 100 Personen mit AUD.

Ergebnisse

Primärendpunkt PHDD über 10 Wochen: kein signifikanter Unterschied zwischen den Gruppen. Sekundär ebenfalls keine signifikanten Unterschiede bei AUD-Symptomen, Folgen, Craving, Stimmung, Schlaf, Schmerz oder Substanzkonsum; Anger und physische Aggression am Studienende niedriger.

Schlussfolgerung der Autor:innen

Intranasales Oxytocin war gut verträglich, reduzierte Trinken oder AUD-bezogene Outcomes aber nicht signifikant. Höhere Dosen, längere Behandlung oder größere Studien könnten erforderlich sein.

Kernaussagen

  • Kein signifikanter Unterschied im primären Endpunkt PHDD
  • Keine signifikanten Effekte auf die meisten sekundären Outcomes
  • Unerwünschte Ereignisse mild und in beiden Gruppen ähnlich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alcohol, Clinical and Experimental Research, online erschienen am 15.07.2026. Verfasst von Nassima Ait-Daoud Tiouririne und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Leading Edge Addiction Research, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Oxytocin, Alcoholism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The neuropeptide oxytocin offers a potentially effective treatment for alcohol use disorder (AUD). Acting centrally in the brain, oxytocin mediates a range of behavioral effects, including reward, stress response, social affiliation, learning, memory, and addictive behaviors. Animal studies demonstrate oxytocin's ability to reduce alcohol consumption, but results in human trials have been mixed. Some studies report reductions in withdrawal symptoms, heavy drinking, and craving, whereas others show no effects. The purpose of this 12‐week clinical trial was to evaluate the efficacy and safety of intranasal oxytocin in individuals with AUD.

Methods

Oxytocin (up to 70 International Units [IU]/day) or placebo was administered to 100 individuals diagnosed with AUD in a double‐blind, randomized, 12‐week multisite trial. The primary outcome was the weekly percentage of heavy drinking days (PHDD) over 10 weeks of maintenance treatment. Secondary outcomes included additional drinking measures, urge to drink, psychological assessments, alcohol‐related consequences, nicotine use, and safety and tolerability of intranasal oxytocin.

Results

No significant differences were observed in PHDD between groups during the 10‐week maintenance phase. However, a small, numerically greater reduction in drinking was seen in the oxytocin group compared with placebo from weeks 9 to 12. Similar patterns were found across secondary drinking outcomes. No significant differences were observed in AUD symptoms, alcohol‐related consequences, craving, mood, sleep, pain, or substance use. At the end of treatment, participants receiving oxytocin scored significantly lower on measures of anger and physical aggression. Oxytocin was well tolerated; adverse events were mild and comparable across groups. The most common event in both groups was hyposmia.

Conclusion

Intranasal oxytocin was well tolerated but did not significantly reduce drinking or AUD‐related outcomes. Higher doses, longer treatment duration, or larger trials may be required to identify responsive subgroups and determine oxytocin's efficacy in AUD. Trial Registration ClinicalTrials.gov , Identifier: NCT03878316. Registered March 14, 2019 ( https://clinicaltrials.gov/ct2/show/NCT03878316 )

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxytocinAlcoholismHumansDouble-Blind MethodMaleAdministration, IntranasalFemaleTreatment OutcomeAdultMiddle Aged

Stichwörter der Autor:innen

alcohol use disorderclinical trialmedication developmentoxytocin

Substanzen

Oxytocin

Autor:innen und Institutionen

  • Center for Leading Edge Addiction Research, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Psychology, University of California Los Angeles, Los Angeles, California, USA.
  • Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Nassima Ait-Daoud Tiouririne, Lara Ray

Förderung

  • NICHD NIH HHS
  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Tiouririne, N. A., Legan, J. A., Devine, E., Lee, K., Weerts, E. M., Ellis, J. D., Ray, L., Shoptaw, S., Falk, D., Ryan, M., Litten, R., Seneviratne, C., Ransom, J., & Scott, C. (2026). Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Multisite Trial Assessing Efficacy and Safety. Alcohol, Clinical and Experimental Research, 50(7). https://doi.org/10.1111/acer.70326

Vancouver

Tiouririne NA, Legan JA, Devine E, Lee K, Weerts EM, Ellis JD, et al. Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Multisite Trial Assessing Efficacy and Safety. Alcohol, Clinical and Experimental Research. 2026;50(7). doi:10.1111/acer.70326

BibTeX
@article{Tiouririne2026,
  author = {Tiouririne, Nassima Ait-Daoud and Legan, Jospeh A and Devine, Eric and Lee, Kristen and Weerts, Elise M and Ellis, Jennifer D and Ray, Lara and Shoptaw, Steve and Falk, Daniel and Ryan, Megan and Litten, Raye and Seneviratne, Chamindi and Ransom, Janet and Scott, Charles},
  title = {Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Multisite Trial Assessing Efficacy and Safety},
  journal = {Alcohol, Clinical and Experimental Research},
  year = {2026},
  volume = {50},
  number = {7},
  doi = {10.1111/acer.70326}
}
Kostenlos starten →